Dry powder inhalation of colistin sulphomethate in healthy volunteers: A pilot study

International Journal of Pharmaceutics

Volumn 335, Issue 1-2, 2007, Pages 41-45

  Westerman, E M ^a,b   de Boer, A H ^c   Le Brun, P P H ^a,b   Touw, D J ^a,b   Frijlink, H W ^c   Heijerman, H G M ^b  

^a Apotheek Haagse Ziekenhuizen   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Colistin sulphomethate; Cystic fibrosis; Dry powder inhalation; Twincer inhaler

Indexed keywords

COLISTIMETHATE;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN EXPERIMENT; LASER DIFFRACTION; LUNG FUNCTION TEST; MALE; NEBULIZATION; NEBULIZER; NORMAL HUMAN; PATIENT COMPLIANCE; PILOT STUDY; POWDER INHALER; PRIORITY JOURNAL; SINGLE DRUG DOSE; VOLUNTEER;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; COLISTIN; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG; MALE; MODELS, BIOLOGICAL; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PILOT PROJECTS; POWDERS; REFERENCE VALUES; RESPIRATORY FUNCTION TESTS; TIME FACTORS;

EID: 33947574266     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.11.021     Document Type: Article

References (24)

1. Abbott J., Dodd M., Bilton D., and Webb A.K. Treatment compliance in young adults with cystic fibrosis. Thorax 49 (1994) 115-120
2. Auty R.M., Brown K., Neale M.G., and Snashall P.D. Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the Spinhaler. Br. J. Dis. Chest 81 (1987) 371-380
3. Barnett M., Bushby S.R., and Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Br. J. Pharmacol. 23 (1964) 552-574
4. Beveridge E.G., and Martin A.J. Sodium sulphomethyl derivatives of polymyxins. Br. J. Pharm. Chemother. 29 (1967) 125-135
5. Brand P., Friemel I., Meyer T., Schulz J., Heyder J., and Häuβinger K. Total deposition of therapeutic particles during spontaneous and controlled inhalations. J. Pharm. Sci. 89 (2000) 724-730
6. Burrows J.A., Bunting J.P., Masel P.J., and Bell S.C. Nebulised dornase alpha: adherence in adults with cystic fibrosis. J. Cyst. Fibros. 1 (2002) 255-259
7. Conway S.P., Pond M.N., Hamnett T., and Watson A. Compliance with treatment in adult patients with cystic fibrosis. Thorax 51 (1996) 29-33
8. ®) with multiple air classifier technology for high powder doses. Eur. J. Pharm. Sci. 28 (2006) 171-178
9. Hodson M.E., Gallagher C.G., and Govan J.R.W. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 20 (2002) 658-664
10. Kucharczyk N. Estimation of the lower limit of quantitation, a method detection performance parameter for biomedical assays, from calibration curves. J. Chromatogr. 612 (1993) 71-76
11. Le Brun P.P.H., Vinks A.A.T.M.M., Touw D.J., Hekelaar N., Mannes G.P.M., Brimicombe R.W., Frijlink H.W., and Heijerman H.G.M. Can tobramycin inhalation be improved with a jet nebulizer?. Ther. Drug Monit. 21 (1999) 618-624
12. Le Brun P.P.H., De Graaf A.I., and Vinks A.A.T.M.M. A high performance liquid chromatographic method for the determination of colistin in serum. Ther. Drug. Monit. 22 (2000) 589-593
13. Le Brun P.P.H., De Boer A.H., Mannes G.P.M., De Fraîture D.M.I., Brimicombe R.W., Touw D.J., Vinks A.A.T.M.M., Frijlink H.W., and Heijerman H.G.M. Dry powder inhalation of antibiotics in cystic fibrosis therapy. Part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur. J. Pharm. Biopharm. 54 (2002) 25-32
14. Li J., Kingsley C., Milne R., Nation R.L., Conway S., Peckham D., Etherington C., and Turnidge J. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother. 52 (2003) 987-992
15. Lipworth B.J. Pharmacokinetics of inhaled drugs. Br. J. Clin. Pharmacol. 42 (1996) 697-705
16. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
17. Mukhopadhyay S., Singh M., Cater J.I., Ogston S., Franklin M., and Olver R.E. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax 51 (1996) 364-368
18. Proost J.H., and Meijer D.K.F. MWPharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput. Biol. Med. 22 (1992) 155-163
19. Quanjer P.H., Tammeling G.J., Cotes J.E., et al. Lung volumes and forced ventilatory flows. Eur. Respir. J. 9 (1993) 5-40
20. Reed M.D., Stern R.C., O'Riordan M.A., and Blumer J.L. The pharmacokinetics of colistin in patients with cystic fibrosis. J. Clin. Pharmacol. 41 (2001) 645-654
21. Sarinas P.S., Robinson T.E., Clark A.R., Canfield J., Chitkara R.K., and Fick R.B. Inspiratory flow rate and dynamic lung function in cystic fibrosis and chronic obstructive lung diseases. Chest 114 (1998) 988-992
22. Schwartz B.S., Warren M.R., and Barkley F.A. Microbiological and pharmacological studies of colistin sulphate and sodium colistin methanesulfonate. Antibiot. Annu. 7 (1959-1960) 41-60
23. Touw D.J., Brimicombe R.W., Hodson M.E., Heijerman H.G., and Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur. Respir. J. 8 (1995) 1594-1604
24. Westerman E.M., Le Brun P.P.H., Touw D.J., Frijlink H.W., and Heijerman H.G.M. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J. Cyst. Fibros. 3 (2004) 23-28